Marker involved in lymphatic system connected to heart failure

March 07, 2018

Researchers at Lund University in Sweden have found a new marker in the blood that is associated with an increased risk of heart failure. Surprisingly, the marker is not directly involved in how the heart functions, unlike most of the previously known markers. Instead, the new marker affects processes in the lymphatic system.

Heart failure is a condition in which the heart is unable to pump a sufficient supply of blood around the body. The symptoms can be vague and there are many possible causes. Researchers at Lunds University have therefore looked for markers, or signal substances in blood, that can help to detect heart failure more rapidly.

"We saw a clear connection in the analyses between a certain marker, a growth factor for lymphatic vessels called VEGF-D, and the risk of developing heart failure. This applied particularly to women", says Yan Borné, researcher at Lund University. The results have been published in the Journal of the American College of Cardiology, JACC.

The growth factor in question is involved in endothelial growth, regulating how the cells on the inside of the vessels grow.

"Previous markers for heart failure have been primarily related to the heart and the strain the heart is subjected to. We started with the lymphatic system instead and the fact that people with heart failure retain fluid. The marker we identified affects the lymphatic vessels so that they in turn help the body to remove fluid, from the legs for example", says Gunnar Engström, Professor of Cardiovascular Epidemiology at Lund University.

In the epidemiological study, the researchers followed 4 265 people over a mean of 20 years (from 1991-1994 till 2014) in the Malmö Diet and Cancer Study. Using proteomics, which makes it possible to map a large number of proteins from a small blood sample, the researchers could measure the marker in question among the subjects, who had not been previously diagnosed with heart failure. The results showed that subjects with a raised level of VEGF-D had an increased risk of subsequently developing heart failure.

The researchers also studied a group of 430 patients with breathing difficulties who visited the emergency room at Skåne University Hospital in Malmö in 2013-2014. Of the 430 patients, 152 were given a diagnosis of heart failure. These people also had a raised level of VEGF-D. Yan Borné says that in the group with a raised level of VEGF-D, the likelihood of heart failure was four times greater than for those with a lower level of the marker.

"The results indicate that this marker could be used at an early stage to predict future heart failure, in view of how it affects the lymphatic system. We hope that in time the discovery will lead to a faster diagnosis at emergency departments", says Yan Borné.

The next step, in addition to replicating the results, will be to investigate if there are genetic causes linked to the growth factor VEGF-D and the risk of developing heart failure.

"We have seen a connection between heart failure and the marker. However, we do not know exactly how the mechanism works between them - this remains to be investigated", concludes Yan Borné.
-end-


Lund University

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.